New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained ...

A new study shows that tiny gold particles could circumvent damaged photoreceptors in patients with macular degeneration and ...

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

and diabetic macular edema (DME). 2 The company has also filed an application with the FDA for the use of pre-filled syringes (PFS) of high-dose aflibercept with the US. Approval and launch of these ...

Individuals who developed vs did not develop postoperative delirium exhibited thicker preoperative macular thickness in the right eye. HealthDay News — In older patients undergoing surgery ...

Follow-up continued until an event, death, or study end in 2019. Among 8873 patients with diabetic macular edema treated using intravitreal anti-vascular endothelial growth factor (VEGF) therapy ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an ...